These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2951123)

  • 1. Home blood glucose monitoring in non-insulin-dependent diabetics: the effect of gliclazide on blood glucose and weight control, a multicentre trial.
    Shaw KM; Wheeley MS; Campbell DB; Ward JD
    Diabet Med; 1985 Nov; 2(6):484-90. PubMed ID: 2951123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes.
    McAlpine LG; McAlpine CH; Waclawski ER; Storer AM; Kay JW; Frier BM
    Eur J Clin Pharmacol; 1988; 34(2):129-32. PubMed ID: 3289948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is sulphonylurea therapy effective long term? A 3-year study with gliclazide.
    Zurro Hernandez J; Lavielle R
    Curr Med Res Opin; 1986; 10(5):351-8. PubMed ID: 3816294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
    van der Wal PS; Heine RJ
    Diabetes Res Clin Pract; 2001 May; 52(2):103-11. PubMed ID: 11311964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure.
    Chazan AC; Gomes MB
    Braz J Med Biol Res; 2001 Jan; 34(1):49-56. PubMed ID: 11151028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up.
    Quatraro A; Consoli G; Ceriello A; Giugliano D
    Diabete Metab; 1986 Dec; 12(6):315-8. PubMed ID: 3545931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
    Betteridge DJ; Vergès B
    Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unchanged gene expression of glycogen synthase in muscle from patients with NIDDM following sulphonylurea-induced improvement of glycaemic control.
    Vestergaard H; Lund S; Bjørbaek C; Pedersen O
    Diabetologia; 1995 Oct; 38(10):1230-8. PubMed ID: 8690177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic cause of hyperglycaemia and response to treatment in diabetes.
    Pearson ER; Starkey BJ; Powell RJ; Gribble FM; Clark PM; Hattersley AT
    Lancet; 2003 Oct; 362(9392):1275-81. PubMed ID: 14575972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.
    Hosker JP; Rudenski AS; Burnett MA; Matthews DR; Turner RC
    Metabolism; 1989 Aug; 38(8):767-72. PubMed ID: 2668699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD.
    Noury J; Nandeuil A
    Diabete Metab; 1991 May; 17(1 Pt 2):209-12. PubMed ID: 1936478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
    Langtry HD; Balfour JA
    Drugs; 1998 Apr; 55(4):563-84. PubMed ID: 9561345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of middle-term gliclazide treatment on insulin secretion in non-insulin dependent diabetics.
    Brogard JM; Pinget M; Dorner M
    Curr Med Res Opin; 1984; 9(1):56-63. PubMed ID: 6373160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas.
    Akanuma Y; Kosaka K; Kanazawa Y; Kasuga M; Fukuda M; Aoki S
    Diabetes Res Clin Pract; 1988 Jul; 5(2):81-90. PubMed ID: 3416710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metabolic effects of gliclazide in diabetes type II patients. Study with indirect calorimetry].
    Golay A; Broquet C; Chabot V; Studer S; Felber JP
    Schweiz Med Wochenschr; 1984 Feb; 114(8):261-4. PubMed ID: 6369531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study.
    Larkins RG; Jerums G; Taft JL; Godfrey H; Smith IL; Martin TJ
    Diabetes Res Clin Pract; 1988 Jan; 4(2):81-7. PubMed ID: 3125029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of weight gain with gliclazide treatment for 30 months in type II diabetes.
    Robb GH; Lowe SM
    Curr Med Res Opin; 1984; 9(1):7-9. PubMed ID: 6723350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoglycemia in Frail Elderly Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea.
    van Dijk P; Bouma A; Landman GW; Groenier KH; Bilo H; Kleefstra N; van Hateren KJ
    J Diabetes Sci Technol; 2017 Mar; 11(2):438-439. PubMed ID: 27625346
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical efficacy of glimepiride].
    Kaneko T; Sakamoto N
    Nihon Rinsho; 1997 Nov; 55 Suppl():152-7. PubMed ID: 9434460
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of gliclazide on plasma insulin, intact and 32/33 split proinsulin in South Asian subjects with Type 2 diabetes mellitus.
    Ammari F; Davies MJ; Koppiker N; Gregory R; Burden AC
    Diabet Med; 1999 Feb; 16(2):142-6. PubMed ID: 10229308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.